Newswire (Published: Friday, February 15, 2019, 9:30:00 AM CST, Received: Friday, February 15, 2019, 9:30:26 AM CST)
Word Count: 346
Results form the Phase III ARCHES trial has shown that enzalutamide taken along with androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or mortality.
Prostate cancer develops when cells in the prostate begin to grow in an uncontrolled way. The cells often grown slowly initially, and thus may not cause problems or symptoms. But, over time, or even in certain men, these cells grow very quickly, and thus the cancer spreads and needs treatment to stop its spread outside the prostate.
Prostate cancer is considered metastatic once the cancer has spread outside of the prostate gland to other parts of the body. Men are considered hormone (or castration) sensitive if their disease still responds to medical or surgical castration to lower testosterone levels.
“The ARCHES trial demonstrated that enzalutamide plus standard hormonal therapy delayed disease progression and if approved has the potential to be an important treatment option for men with prostate cancer that has spread but has not yet become hormone resistant,” said Dr
Adverse events (AEs) in the
Enzalutamide is currently approved in
The results of the study are due to be presented at the 2019 Genitourinary Cancers Symposium in
The post Phase III combination trial improves survival in men with metastatic prostate cancer appeared first on European Pharmaceutical Review.